1. Taking a BiTE out of the CAR T space race;Patel A;Br J Haematol,2021
2. Teclistamab in relapsed or refractory multiple myeloma;Moreau P;N Engl J Med,2022
3. FDA Approves Teclistamab-cqyv for Relapsed or Refractory Multiple Myeloma. (2022). Accessed. June 1, 2023: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-teclistamab-cqyv-relapsed-or-refractory-m....
4. Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-1). (2023). Accessed. June 1, 2023: https://www.clinicaltrials.gov/ct2/show/NCT03145181.
5. A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-1). Accessed. June 1, 2023: https://clinicaltrials.gov/ct2/show/NCT04557098.